Cleared Traditional

K243518 - BinaxNOW COVID-19 Antigen Self Test

K243518 is an FDA 510(k) clearance for BinaxNOW COVID-19 Antigen Self Test, manufactured by Abbott Diagnostics Scarborough, Inc.. The device is a Class 2 Microbiology device with product code QYT cleared through the Traditional 510(k) pathway after a 90-day FDA review.

K243518 · Abbott Diagnostics Scarborough, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 2025
Decision
90d
Days
Class 2
Risk

K243518 is an FDA 510(k) clearance for the BinaxNOW™ COVID-19 Antigen Self Test. Classified as Over-the-counter Covid-19 Antigen Test (product code QYT), Class II - Special Controls.

Submitted by Abbott Diagnostics Scarborough, Inc. (Scarborough, US). The FDA issued a Cleared decision on February 11, 2025 after a review of 90 days - within the typical 510(k) review window.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3984 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Abbott Diagnostics Scarborough, Inc. devices

FDA 510(k) Submission Details - K243518

510(k) Number K243518 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 13, 2024
Decision Date February 11, 2025
Days to Decision 90 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
12d faster than avg
Panel avg: 102d · This submission: 90d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

QYT Device Classification - Class 2, Special Controls

Product Code QYT Over-the-counter Covid-19 Antigen Test
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3984
Definition For The Rapid, Qualitative Detection Of Sars-cov-2 Virus Nucleocapsid Protein Antigen In Individuals 2 Years And Older.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - QYT Over-the-counter Covid-19 Antigen Test

All 13
Devices cleared under the same product code (QYT) and FDA review panel - the closest regulatory comparables to K243518.
COVID-19 Detect Rapid Self -Test
K251595 · InBios International, Inc. · Oct 2025
GenaCheck COVID-19 Rapid Self-Test
K251753 · Genabio Diagnostics, Inc. · Sep 2025
OHC COVID-19 Antigen Self Test
K241313 · Osang, LLC · May 2025
CareSuperb™ COVID-19 Antigen Home Test
K241915 · Access Bio, Inc. · Jan 2025
Wondfo 2019-nCoV Antigen Test (Lateral Flow Method)
K241317 · Guangzhou Wondfo Biotech Co., Ltd. · Sep 2024
CorDx Tyfast COVID-19 Ag Rapid Test
K240728 · CorDx, Inc. · Jun 2024